DexCom, Inc.
DXCM
Rang in aandelen
#759
DexCom, Inc. is a medical technology company primarily focused on innovating,... DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Aandeelprijs
$85.72
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$32.35B
Verandering (1 dag)
-0.30%
Verandering (1 jaar)
22.90%
Land
US
Handel DexCom, Inc. (DXCM)
Categorie
Healthcare
Aantal uitstaande aandelen voor DexCom, Inc. (DXCM)
Aantal uitstaande aandelen per June 2026: 383.70M
Volgens de laatste financiële rapporten en de aandelenkoers van DexCom, Inc. bedraagt het huidige aantal uitstaande aandelen 383.70M. Aan het einde van December 2024 had het bedrijf 404.63M uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van DexCom, Inc. (DXCM) van 2000 tot 2026
Uitstaande aandelen aan het einde van elk jaar
| Jaar | Uitstaande aandelen | Wijzigen |
|---|---|---|
| 2026 (TTM) | 383.70M | -1.67% |
| 2025 | 390.20M | -3.57% |
| 2024 | 404.63M | 4.83% |
| 2023 | 386.00M | -0.87% |
| 2022 | 389.40M | 0.65% |
| 2021 | 386.90M | 2.46% |
| 2020 | 377.60M | 3.62% |
| 2019 | 364.40M | 3.29% |
| 2018 | 352.80M | 2.20% |
| 2017 | 345.20M | 3.23% |
| 2016 | 334.40M | 4.76% |
| 2015 | 319.20M | 6.12% |
| 2014 | 300.80M | 5.77% |
| 2013 | 284.40M | 3.49% |
| 2012 | 274.80M | 4.73% |
| 2011 | 262.40M | 15.29% |
| 2010 | 227.60M | 28.31% |
| 2009 | 177.39M | 50.40% |
| 2008 | 117.95M | 4.15% |
| 2007 | 113.25M | 3.95% |
| 2006 | 108.94M | 43.77% |
| 2005 | 75.78M | 728.71% |
| 2004 | 9.14M | 5.35% |
| 2003 | 8.68M | 6.05% |
| 2002 | 8.18M | 7.89% |
| 2001 | 7.59M | 9.81% |
| 2000 | 6.91M | 0.00% |
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Uitstaande aandelen | Verschil | Land |
|---|---|---|---|
| 1.74B | 354.27% |
US
|
|
| 1.28B | 234.14% |
IE
|
|
| 383.50M | -0.05% |
US
|
|
| 1.48B | 285.09% |
US
|
|
| - | - |
DE
|
